<DOC>
	<DOCNO>NCT00602472</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 1356 ( 5 mg daily ) compare placebo give 24 week add-on therapy metformin combination sulphonylurea patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>BI 1356 ( Linagliptin ) Combination With Metformin Sulphonylurea Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient diagnosis type 2 diabetes mellitus , currently treat stable total daily dose preferably* &gt; /= 1500 mg metformin dose sulphonylurea drug document , Investigator , individual maximum tolerate dose sulphonylurea drug . Both dose dose regimen metformin sulphonylurea must stable ( i.e . unchanged ) 10 week prior inform consent , must change duration trial 2 . Glycosylated haemoglobin A1 ( HbA1c ) &gt; /= 7.0 &lt; /= 10.0 % screen Visit 1a Visit 2 ( start placebo runin phase ) 3 . Age &gt; /= 18 &lt; /= 80 year Visit 1a ( screen ) 4 . BMI ( Body Mass Index ) &lt; /= 40 kg/m2 Visit 1a ( screen ) 5 . Signed date write informed consent , late date Visit 1a , accordance GCP local legislation *Patients currently treat total daily dose less 1500 mg metformin include trial Investigator document dose maximum tolerate dose metformin patient . Exclusion criterion : 1 . Myocardial infarction , stroke TIA ( transient ischaemic attack ) within 6 month prior date inform consent 2 . Impaired hepatic function , define serum level either alanine transaminase ( ALT/SGPT ) , aspartase transaminase ( AST/SGOT ) , alkaline phosphatase ( ALP ) 3 time upper limit normal ( ULN ) , determine Visit 1a 3 . Renal failure renal impairment ( serum creatinine &gt; /= 1.5 mg/dl ) determine Visit 1a 4 . Treatment rosiglitazone pioglitazone within 3 month prior date inform consent 5 . Treatment GLP1 analogue ( e.g . exenatide ) within 3 month prior date inform consent 6 . Treatment insulin within 3 month prior date inform consent 7 . Treatment antiobesity drug ( e.g . sibutramine , rimonabant , orlistat ) within 3 month prior date inform consent 8 . Current treatment systemic steroid ( i.e . time informed consent ) change dosage thyroid hormone within 6 week prior date inform consent 9 . Premenopausal woman ( last menstruation &lt; /= 1 year prior date informed consent ) : nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence vasectomise partner . No exception make . 10 . Known hypersensitivity allergy investigational product excipients trial background therapy ( i.e . metformin combination sulphonylurea ) sulphonamides 11 . Dehydration ( confirm Investigators clinical opinion ) 12 . Current acute chronic metabolic acidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>